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Introduction
Greater molecular understanding of cardiac mechano-
transduction in normal and failing hearts has provided novel 
perspectives on the role of cyclic guanosine monophosphate 
(cGMP)-protein kinase G (PKG) signalling in heart failure 
with preserved ejection fraction, i.e. HFpEF ([1–5]; Fig. 1).
While initial descriptions of HFpEF focused on left 
ventricular (LV) diastolic dysfunction, it is now clear that 
HFpEF actually involves a complex interplay of factors, 
including LV and vascular stiffness, left atrial impairment, 
chronotropic incompetence and decreased pulmonary 
vascular capacitance [6]. Recent echocardiographic speckle 
tracking studies have shown that global LV function in 
HFpEF suffers from a loss of longitudinal shortening that 
is compensated by radial and circumferential shortening 
[6], together with a loss of LV twist and untwist during 
systole and diastole, thus indicating damage primarily to the 
subendocardial muscle fibres. HFpEF is now understood to 
have a characteristic set of features including LV hypertrophy, 
concentric remodelling, increased extracellular matrix 
(ECM), abnormal calcium handling, abnormal relaxation 
and filling and decreased diastolic distensibility ([6]; Fig. 1). 
Diastolic function is often conceptualised as the totality of 
an active process of pressure decay (relaxation) during early 
diastole, which is related to myofilament dissociation and 
calcium reuptake, and to a ‘passive’ stiffness dependent 
on viscoelastic properties, and modulated by mechanical 
changes via the sarcomere, ECM, chamber or pericardium 
[6]. By contrast, diastolic abnormalities in HFpEF include 
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Abstract Heart failure with preserved ejection fraction, 
i.e. HFpEF, is highly prevalent in ageing populations, ac-
counting for more than 50 % of all cases of heart failure 
in Western societies, and is closely associated with comor-
bidities such as obesity, diabetes and arterial hypertension. 
However, all large multicentre trials of potential HFpEF 
treatments conducted to date have failed to produce posi-
tive outcomes. These disappointing results suggest that 
a ‘one size fits all’ strategy may be ill-suited to HFpEF 
and support the use of tailored, personalised therapeutic 
approaches with specific treatments designed for specific 
comorbidity-related HFpEF phenotypes. The accumulation 
of a multitude of cardiovascular comorbidities over time 
leads to increased systemic inflammation, oxidative stress 
and coronary microvascular endothelial inflammation, 
eventually resulting in degradation of cyclic guanosine 
monophosphate (cGMP) via multiple pathways, thereby re-
ducing protein kinase G (PKG) activity. The importance of 
cGMP-PKG pathway modulation is supported by growing 
evidence that suggests that this pathway may be a promis-
ing therapeutic target, evidence that is mainly based on its 
role in the phosphorylation of the giant cytoskeletal protein 
titin. This review will focus on the preclinical and early 
clinical evidence in the field of cGMP-enhancing therapies 
and PKG activation.
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degree of collagen crosslinking are all increased in HFpEF 
and aortic stenosis (Fig. 1), and have been linked to diastolic 
LV dysfunction [8–10]. In addition, myocardial collagen 
deposition in HFpEF results from the differentiation of 
fibroblasts into myofibroblasts due to release of transforming 
growth factor β by monocytes migrating through the inflamed 
microvascular endothelium ([11, 12]; Fig. 1). Microvascular 
inflammation also favours the proliferation of fibroblasts and 
myofibroblasts as a direct consequence of reduced nitric oxide 
(NO) bioavailability and the subsequent unopposed profibrotic 
actions of growth-promoting hormones such as endothelin-1, 
angiotensin II and aldosterone ([11, 12]; Fig. 1).
delayed early relaxation, myocardial and myocyte stiffening, 
and associated changes in filling dynamics ([6]; Fig. 1).
In diastole, the ECM contributes to passive stiffness, 
helping to prevent overstretch, myocyte slippage and tissue 
deformation during ventricular filling. ECM components 
also serve as modulators of growth and tissue differentiation. 
Certain forms of excessive collagen deposition are associated 
with the chronic pressure overload that occurs in hypertensive 
heart disease and aortic stenosis, leading to an increase in 
myocardial stiffness. Collagen is a major determinant of ECM-
based stiffness, and factors such as total collagen levels, the 
expression of collagen type I relative to type 3 [7], and the 
KEY MESSAGE  Signalling pathways of cGMP-PKG through which the titin springs can be phosphorylated, and
possible strategies to enhance the cGMP pool.
Fig. 1 Classes of drugs 
that modulate the cGMP-
PKG pathway within the 
cardiomyocyte. Cyclic guanosine 
monophosphate (cGMP) is 
produced either via cytosolic 
soluble guanylate cyclase (sGC), 
which is activated by nitric oxide 
(NO) or by the transmembrane 
particulate guanylate cyclase 
(pGC), which is activated by 
the natriuretic peptides (ANP, 
BNP). Class of NO and nitroxyl 
donors is displayed by No. 1. 
sGC stimulators (No. 2) target 
only non-oxidised sGC (Fe2+); 
vice versa sGC activators (No. 
3) target oxidised sGC (Fe3+) by 
reactive oxygen species (ROS). 
Inhibitors of neprilysin (NEP) 
responsible for ANP and BNP 
breakdown are indicated by No. 
4. Phosphodiesterase 5 (PDE5) 
operates the breakdown of cGMP 
produced by sGC, while PDE9 
is responsible for the breakdown 
of cGMP produced by pGC (No. 
5). 5’GMP guanosine 5’-mono-
phosphate, Ang-II angiotensin II, 
Ca2+ calcium, ECM extracellular 
matrix, ET-1 endothelin-1, GTP 
guanosine triphosphate, HFpEF 
heart failure with preserved 
ejection fraction, IC intracellular, 
LTCC L-type calcium channel, 
P phosphate group, PLB 
phospholamban, PKG protein 
kinase G, SERCA2a sarco/
endoplasmic reticulum Ca2+-
ATPase, SR sarco/endoplasmic 
reticulum, RyR2 ryanodine 
receptor 2, TGF β transforming 
growth factor β.
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of target proteins, exerting a wide range of downstream 
effects such as inhibition of the L-type calcium channel, 
enhancement of intracellular diastolic calcium reuptake 
through phosphorylation of phospholamban, suppression 
of hypertrophic signalling through inhibition of G-protein 
coupled receptors and the transient receptor potential 
canonical channel, inhibition of ischaemia-reperfusion 
injury through phosphorylation of the ATP-sensitive 
potassium channel and stimulation of LV relaxation and 
distensibility by phosphorylation of troponin I (TnI) and 
titin ([19, 20]; Fig. 1).
cGMP and HFpEF pathophysiology
One finding of potential clinical importance was the 
favourable reaction of slow LV relaxation and high diastolic 
LV stiffness in HFpEF to increased PKG activity following 
in vivo administration of the PDE5A inhibitor sildenafil, 
which facilitates increased myocardial PKG activity by 
inhibiting the breakdown of cGMP by PDE5A [1–5]. This is 
significant, because relative to both aortic stenosis and heart 
failure with reduced ejection fraction (HFrEF) [5], HFpEF 
patients show reduced myocardial PKG activity and lower 
cGMP concentrations, both of which are associated with 
increased titin-based stiffness, titin hypophosphorylation and 
elevated myocardial nitrotyrosine levels, indicative of raised 
nitrosative/oxidative stress [5]. Another important finding 
was the demonstration of the reduced bioavailability of NO in 
HFpEF patients and in an HFpEF animal model, suggesting 
that impaired cGMP-PKG signalling in HFpEF is related to 
the low myocardial NO bioavailability that results from high 
nitrosative/oxidative stress [21]. All of these findings were 
associated with titin hypophosphorylation (Fig. 1). A further 
related finding was that the accumulation of a variety of 
cardiovascular comorbidities such as ageing, hypertension, 
diabetes, obesity and physical inactivity (which limit NO 
bioavailability and thereby decrease PKG activity in adjacent 
cardiomyocytes) has been mechanistically linked to the 
classical hallmarks of LV stiffness and diastolic dysfunction, 
which include concentric LV remodelling and cardiomyocyte 
stiffening due to titin hypophosphorylation [1–5, 10, 12, 19, 
22]. Taken together, these findings suggest that PKG-mediated 
phosphorylation of titin could be a therapeutic target in HFpEF, 
although the elements of the NO-cGMP-PKG signalling net-
work most critical to titin phosphorylation and stiffness still 
need to be elucidated.
Is PDE inhibition beneficial for HFpEF?
The relevance of the NO-cGMP-PKG signalling network 
is further emphasised by the actions of sildenafil in many 
Oxidative stress-mediated cell signalling in 
comorbidities associated with HFpEF
Patients with HFpEF show characteristic features, being 
generally elderly, more often female, and display a high 
prevalence of non-cardiac comorbidities such as overweight/
obesity, hypertension, diabetes, chronic obstructive 
pulmonary disease, anaemia and chronic kidney disease. 
Interestingly, systemic inflammation and endothelial 
dysfunction are important hallmarks of these comorbidities, 
and may also drive myocardial dysfunction and remodelling 
in HFpEF through coronary microvascular endothelial 
inflammation [11, 12]. This latter effect is evident in 
the reduced aortic distensibility, higher arterial load and 
deficient vasodilatory reserve seen in HFpEF, which may 
be due to upregulation of endothelial NO synthase (NOS) 
[11, 12]. It has been suggested that control of cardiovascular 
risk factors and comorbidities in HFpEF, such as body 
mass index, smoking and atrial fibrillation, may provide a 
successful therapeutic strategy as these have been identified 
as traditional triggers for new-onset HFpEF; these factors 
are therefore likely to be important in the prevention and 
treatment of HFpEF [12, 13].
Considerable evidence now supports a role for oxidative 
stress and inflammation in HFpEF progression, in addition 
to the endothelial dysfunction that is common to many forms 
of vascular disease [12, 14, 15]. Endothelial dysfunction 
is thought to be independent of a specific aetiology and 
vascular structure, and may be due to altered oxidative 
stress processes that result in impaired NO function [12, 
14, 15]. Oxidative stress-mediated downregulation of NO-
cGMP-PKG signalling has been demonstrated in various 
experimental models of diabetes, insulin resistance, obesity 
and metabolic syndrome [1–4, 12, 14, 15]. Reduced NO 
function has been attributed to deficiencies in the levels or 
function of NOS signalling enzymes, as well as scavenging 
effects due to an enhanced production of superoxide anion 
or angiotensin II [16, 17]. All of these changes may impair 
cGMP-PKG signalling, potentially explaining its diminished 
function in HFpEF and suggesting a potential therapeutic 
target for this specific form of heart disease (Fig. 1).
cGMP signalling in the cardiomyocyte
cGMP is synthesised by two distinct pathways: the first 
requires activation of soluble guanylate cyclase (sGC) 
by NO, while the second requires particulate guanylate 
cyclase (pGC) coupled to natriuretic peptide (NP) ([18, 
19]; Fig. 1). Well-characterised downstream signalling 
effectors of cGMP include cGMP-dependent PKG, cGMP-
susceptible phosphodiesterases (PDEs), and cGMP-gated 
cation channels (Fig. 1). PKG phosphorylates a vast number 
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regarding gender and comorbidities, in which sildenafil did 
not improve invasive right ventricular haemodynamic para-
meters, nor did it reduce pulmonary arterial pressures when 
HFpEF was complicated with pulmonary hypertension 
[30]. Thus, despite these contradictory observations, the 
possibility remains that sildenafil is effective, but perhaps 
only in HFpEF sub-populations with a specific patient profile 
associated with relevant comorbidities. However, many 
pharmacological strategies for cGMP pathway modulation/
enhancement remain, and the effects of an intervention 
might vary with the mode and pathway site of action. The 
relative importance of possible interventions remains to be 
determined.
PKG activators and strategies to enhance cGMP
One of the abovementioned studies showed that 30 % of 
HFpEF patients have diastolic dysfunction with no increase 
in LV collagen [31], but with increased cardiomyocyte 
stiffness (attributed to titin hypophosphorylation due to 
cGMP-PKG deterioration) [5]. This finding suggests that, 
depending on comorbidities, cGMP-PKG and titin may be 
promising therapeutic targets for heart failure with diastolic 
abnormalities. Boosting myocardial cGMP levels might 
be possible by alternative means, which can be achieved 
through stimulation of pGC activity, through augmentation 
of sGC activity, enhancement of NOS coupling and NO 
production or via inhibition of cGMP degrading enzymes. 
However, this may require the study of possible altered 
proteins in HFpEF that are involved in the stimulation or 
degradation of cGMP and which can be affected by oxidative 
stress (e.g. the expression levels of GC-A and -C receptors, 
sGC, PDE5A and 9A, and NPs including ANP, BNP and 
CNP). A better understanding of these factors would help 
determine which upstream mechanism is responsible for 
reduced cGMP-PKG, and would help dissect the effect 
of risk factors on upstream pathways of cGMP-PKG 
signalling. We expect expression levels of these proteins 
to be distinctive, dependent on the risk factors. The body 
of evidence supporting cGMP enhancement and oxidative 
stress-based comorbidities provides a convincing rationale 
for further investigation of this pathway in HFpEF, but 
will probably require the inhibition and/or activation of 
several cGMP-PKG signalling pathways, and will require 
the identification of those elements of the NO-cGMP-PKG 
signalling network that are critical for improvement of 
diastolic stiffness in vivo.
NO and nitroxyl donors
Previous clinical trials of PDE5A inhibitors, NO donors, sGC 
activators and neprilysin inhibitors have focused on acute 
studies. Inhibition of cGMP degradation enhances NO-
mediated vasodilation by sildenafil, restores LV relaxation 
kinetics in mice exposed to transverse aortic constriction 
[23], and reduces diastolic LV stiffness in an old hyper-
tensive dog model through restored phosphorylation of 
titin [4]. Similar effects have been observed in patients 
with HFrEF and in HFpEF patients with pulmonary 
hypertension [24–26]. PDE5A inhibitors have a range of 
beneficial effects and can attenuate adrenergic stimulation, 
reduce ventricular-vascular stiffening, improve endothelial 
function, reduce pulmonary vascular resistance and enhance 
exercise tolerance in HFrEF [24–26].
Given the known properties of sildenafil, a long-term 
(24-week) trial of sildenafil (RELAX trial) in patients with 
HFpEF reported an unexpected outcome [27], producing 
no evidence for an elevation of the low cGMP content 
expected in HFpEF following inhibition of PDE5A. Indeed, 
in the > 100 HFpEF patients studied, sildenafil failed to 
raise plasma cGMP or ameliorate diastolic LV dysfunction. 
The authors suggested that these disappointing results 
were (partially) attributable to the relatively low right-
sided heart pressures in their patient group compared with 
earlier studies in HFrEF. In addition, elevated basal plasma 
levels of N-terminal pro-BNP (NT-proBNP) and the high 
prevalence of atrial fibrillation in these patients suggested 
that they were already at an advanced stage of HFpEF 
and therefore less likely to benefit from a strategy limited 
to the inhibition of cGMP breakdown via PDE5A. On the 
other hand, this negative outcome may also be due, in 
part, to the fact that PDE5A is expressed at low levels in 
heart failure and myocardial tissues. One explanation for 
the results described above was hinted at recently when it 
was reported that cGMP-specific PDE9A regulates cGMP 
signalling independently of NO and contributes to stress-
induced cardiac disease. Interestingly, PDE9A is increased 
in hypertrophied hearts and in HFpEF patients [28], possibly 
suggesting that continuing expression of PDE9A may have 
contributed to the neutral outcome of the RELAX trial. 
This further suggests that, in addition to PDE5A, PDE9A 
may also be a bona fide therapeutic target in heart failure. 
Conversely, the failure of the RELAX trial might also be 
related to the subcellular microdomains of cGMP recruited 
by inhibition of PDE5A, which are NO dependent and 
therefore ineffective in recruiting a preload reserve under 
conditions of reduced NO bioavailability.
In light of the many caveats surrounding the RELAX 
trial it is worth recalling that other small studies have 
demonstrated benefits of sildenafil in patients with high 
blood pressure, right ventricular dysfunction and pulmonary 
arterial hypertension. In some studies sildenafil was reported 
to be beneficial for right ventricular function and pulmonary 
pressures in HFpEF patients with pulmonary hypertension 
[29]. This is in contrast with a more typical HFpEF population 
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oxidative stress [40, 41]. So far, this class of drugs has 
only been tested in HFrEF patients. In a canine model of 
congestive heart failure, the sGC activator cinaciguat was 
shown to potently unload the heart, increasing cardiac output 
and renal flow without any further neurohormonal activation 
[40, 41]. Early clinical data in acute decompensated heart 
failure showed reduction of filling pressure and an increased 
cardiac output [40, 41]. However, a phase IIb clinical trial 
(COMPOSE) in a similar population was terminated early 
because of excessive hypotension in the cinaciguat arm [42].
Stimulators of sGC reduce renal and cardiac organ damage 
in experimental high and low renin models [43]. Recently, 
a phase IIb clinical study in patients with pulmonary hyper-
tension caused by systolic LV dysfunction found that the 
sGC stimulator, riociguat, failed to reduce pulmonary artery 
pressure, but did cause increases in cardiac index and stroke 
volume, and improved systemic and pulmonary resistance 
[44]. Another oral sGC stimulator, vericiguat, is now under 
investigation in a phase II clinical trial, recruiting both 
HFpEF and HFrEF patients (SOCRATES-PRESERVED 
and -REDUCED, respectively) [45]; however, the latest 
report on the HFrEF study population found no significant 
effect of vericiguat on NT-proBNP levels at 12 weeks of 
dose-finding treatments [46].
NP-mediated cGMP-PKG signalling
ANP and BNP are released by atrial and ventricular 
cardiomyocytes, respectively (Fig. 1), in response to 
increased myocardial wall stress due to volume- or 
pressure-overload conditions, and both induce vasodilation 
and natriuresis, whereas CNP does not induce natriuresis 
at physiological concentrations [47]. The vasopeptidase 
enzyme neprilysin is responsible for the breakdown of 
natriuretic peptides (Fig. 1). The neprilysin inhibitor, 
omapatrilat, which is actually a combined inhibitor of 
angiotensin-converting enzyme and neprilysin, showed 
promising results in HFrEF, but further investigation of this 
compound was hindered by excessive angioedema in a sub-
sequent phase III clinical trial [48, 49]. A new compound, 
LCZ696, which is also a combined angiotensin receptor 
and neprilysin inhibitor, was recently developed and 
tested in a phase II HFpEF trial [48, 49]. The compound 
achieved a greater reduction of NT-proBNP at 12 weeks 
compared with valsartan. In addition, follow-up at 36 weeks 
showed a greater reduction of left atrial volume index, and 
improvements of New York Heart Association functional 
class and estimated glomerular filtration rates [50, 51]. Of 
note, all these changes were independent of reduction in 
systolic blood pressure. A phase III clinical trial in HFpEF 
patients is currently under way and will clarify whether 
these preliminary findings translate to improved outcomes.
vasodilatory effects. This focus is now shifting towards their 
potential direct myocardial effects, independent of afterload 
reduction. Nitroxyl donors, such as 1-nitrosocyclohexyl 
acetate, may have therapeutic benefits in heart failure due to the 
direct action of nitroxyl on myofilaments, sarco/endoplasmic 
reticulum Ca2+-ATPase (SERCA2a) and ryanodine receptor 
2 (RyR2) [32], which all have overall positive inotropic and 
lusitropic effects on the heart. Whether nitroxyl donors are 
beneficial in treating HFpEF still needs to be elucidated. On 
the other hand, the NO donors increase diastolic cell length 
[33], inducing earlier LV relaxation in vitro. In line with this, 
in patients with chest pain but no evidence of coronary lesions, 
intracoronary infusion of sodium nitroprusside resulted in 
a slightly decreased LV peak systolic pressure and an acute 
increase of LV end-diastolic capacitance [34, 35]. In theory, the 
described effects on LV compliance suggest that NO donors 
would be ideal in tackling LV stiffness in HFpEF patients. 
However, major limitations of the available NO donors have 
hindered progress in the field. Firstly, patients with heart 
failure develop a rapid tolerance phenomenon, also termed 
tachyphylaxis, leading to an impaired NO bioactivation that 
is related to increased vascular oxidative stress [6, 12, 13]. 
Secondly, chronic administration of the NO donor isosorbide 
mononitrate was shown to increase oxidative stress and induce 
endothelial dysfunction by increasing the expression of endo-
thelin [36]. Finally, HFpEF patients are sensitive to preload 
reduction and are therefore more susceptible to haemodynamic 
instability and stroke volume reduction following vasodilation 
than HFrEF patients [6, 12, 13]. NO donors remain important 
therapeutic options for vascular unloading and to decrease 
filling pressures in acutely decompensated patients, but are less 
applicable in chronic heart failure. In addition, NO signalling 
has anti-fibrotic, anti-hypertrophic and anti-adrenergic actions 
that oppose adverse cardiac remodelling, and thus may 
represent potential therapeutic strategies for HFpEF [37–39]. 
Furthermore, tetrahydrobiopterin (BH4) and endothelial NOS 
activators could be useful in reducing diastolic dysfunction, 
since the deoxycorticosterone acetate (DOCA)-salt mouse 
model is associated with BH4 depletion and uncoupled NOS 
activity, but BH4 administration consistently reduced DOCA-
salt-associated myosin binding protein C glutathionylation and 
diastolic dysfunction [37–39].
sGC activation and stimulation
The responsiveness of sGC to NO and its subsequent ability 
to generate cGMP is impaired by oxidation (Fig. 1). NOS 
can also become uncoupled due to oxidation, resulting in 
the synthesis of superoxide. sGC activators and stimulators 
are two recently discovered classes of compounds that 
modulate sGC activity.
sGC activators are ideal substitutes for NO under 
conditions of endothelial dysfunction, such as increased 
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will have direct consequences when considering their relative 
therapeutic potentials for improving diastolic function.
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